A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody

Robin Michelet,Klas Petersson,Marc C. Huisman,C. Willemien Menke‐van der Houven van Oordt,Iris H. C. Miedema,Andrea Thiele,Ghazal Montaseri,Alejandro Pérez‐Pitarch,David Busse

DOI: https://doi.org/10.1002/psp4.13285

2024-12-11

CPT Pharmacometrics & Systems Pharmacology

Abstract:In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo. Here, we present the development and application of a minimal physiologically‐based pharmacokinetic (mPBPK) modeling approach to integrate biodistribution data in a quantitative platform to characterize and predict intratumor exposure and receptor occupancy (RO) of BI 754111, an IgG‐based anti‐lymphocyte‐activation gene 3 (LAG‐3) monoclonal antibody (mAb). Specifically, calibration and qualification of the predictions were performed using 89Zr‐labeled BI 754111 biodistribution data, that is, PET‐derived intratumor drug concentration data, tumor‐to‐plasma ratios, and data from Patlak analyses. The model predictions were refined iteratively by the inclusion of additional biological processes into the model structure and the use of sensitivity analyses to assess the impact of model assumptions and parameter uncertainty on the predictions and model robustness. The developed mPBPK model allowed an adequate description of observed tumor radioactivity concentrations and tumor‐to‐plasma ratios leading to subsequent adequate prediction of LAG‐3 RO at different dose levels. In the future, the developed model could be used as a platform for the prediction and analysis of biodistribution data for other mAbs and may ultimately support dose optimization by identifying dosages resulting in saturated RO.

pharmacology & pharmacy